Options to support appropriate opioids prescribing

Query# 18-04: Options to support appropriate opioids prescribing

This project is Phase 2 of Q# 16-07, an earlier project focusing on appropriate prescribing..  The analytical protocol has been finalized and data access has been obtained for analysis. Data analyses are nearly complete.

Our findings so far suggest that the development of chronic opioid use is associated with multiple factors including prescription of long-acting opioids, initial prescription by general practitioners, and female patients aged >75. These data may be helpful for regulators to formulate strategies to limit the development of chronic opioid dependence.

An abstract of preliminary results has been submitted to the International Society for Pharmacoepidemiology annual meeting. The main results were presented to the Opioid Working Group of the Office of Drug Research and Surveillance, Controlled Substances Directorate of Health Canada, on March 28, 2019. An abstract of preliminary results will be presented at the 35th ISPE annual meeting in August. A manuscript describing these results is being finalized for submission to CMAJ.

Phase 2 will look at the following questions:

* What approaches and initiatives are utilized to positively influence appropriate prescribing and reduce unnecessary variations in prescribing?

* Of the different appropriate prescribing initiatives identified is there any evidence of their impact on outcomes measures in Canada?

* How do the different appropriate prescribing initiatives compare on various outcome measures?

* What data are required to inform and support interventions on appropriate prescribing?

* What types of quality indicators are effective in monitoring appropriate prescribing and use?

For more information contact: Jessica (Lifang) Wang. Research Coordinator. [email protected]   514.934.1934 ext.44718